STOCK TITAN
  1. Home
  2. News
  3. GBNH

Greenbrook TMS Inc - GBNH STOCK NEWS

Welcome to our dedicated news page for Greenbrook TMS (Ticker: GBNH), a resource for investors and traders seeking the latest updates and insights on Greenbrook TMS.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Greenbrook TMS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Greenbrook TMS's position in the market.

News
Greenbrook TMS Announces Settlement of Ongoing Litigation
Rhea-AI Summary
Greenbrook TMS Inc. (GBNH) settles breach of contract claim with plaintiff, agreeing to pay approximately $2.2 million in total, including an initial immediate payment of $250,000 and weekly payments of $75,000 up to the maturity date of the promissory note on May 1, 2024. The settlement also involves the dismissal of the Klein Note Action and a mutual release of claims. Additionally, there is a stay on the separate complaint related to the acquisition of Success TMS for up to six months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
none
-
News
GREENBROOK TMS RECEIVES NASDAQ DELISTING NOTICE AND INTENDS TO APPEAL
Rhea-AI Summary
Greenbrook TMS Inc. (NASDAQ: GBNH) received notification from Nasdaq of its delisting due to noncompliance with the Minimum Bid Requirement and the MVLS Requirement. The company has until November 13, 2023, to regain compliance with these requirements. Greenbrook intends to appeal the determination made by Nasdaq pursuant to the procedures set forth in the Nasdaq Listing Rules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
GREENBROOK TMS RAISES US$2.5 MILLION IN DEBT FINANCING
Rhea-AI Summary
Greenbrook TMS Inc. (NASDAQ: GBNH) announced the nineteenth amendment to its credit facility with Madryn Asset Management, securing an additional $2,548,223.35 in senior secured term loans. The amendment also allows for the conversion of a portion of the outstanding principal amount of the new loan into common shares of the company at a conversion price of US$1.90. The amendment further defers the interest payment due date and extends the period during which the company's minimum liquidity covenant is reduced. The proceeds of the new loan will be used for general corporate and working capital purposes. The company is also considering additional near-term financing options to address its future liquidity needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.3%
Tags
none
News
GREENBROOK TMS REPORTS THIRD QUARTER OPERATIONAL AND FINANCIAL RESULTS
Rhea-AI Summary
Greenbrook TMS Inc. (NASDAQ: GBNH) announced its Q3 2023 operational and financial results, including a 13% decrease in quarterly revenue to $18.0 million, a 17% increase in YTD 2023 revenue to $56.3 million, and a 24% decrease in loss for the period. The company also reported the expansion of its Spravato® offering to 56 treatment centers, with plans to reach 70-80 centers by the end of fiscal 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.89%
Tags
earnings
-
News
GREENBROOK TMS RAISES US$2.0 MILLION IN DEBT FINANCING
Rhea-AI Summary
Greenbrook TMS Inc. has entered into the eighteenth amendment to its credit facility with Madryn Asset Management, securing an additional $2,045,685.28 in senior secured term loans. The company now has approximately $67.5 million outstanding under the credit facility. Madryn also has the option to convert up to $6.1 million of the outstanding principal amount of the loans into common shares at a conversion price of $1.90 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
none
-
News
GREENBROOK TMS ANNOUNCES DIRECTOR APPOINTMENT
Rhea-AI Summary
Greenbrook TMS Inc. appoints Surindra Mann as an independent director, filling the vacancy created by the resignation of Dr. Adrienne Graves. Mann is a finance executive with over 20 years of experience in high growth environments, primarily in the medical device industry. She currently serves as the vice-president of global finance at STAAR Surgical. Mann's appointment strengthens the company's board and brings expertise in finance and accounting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.93%
Tags
none
News
GREENBROOK TMS ANNOUNCES DATES FOR ITS THIRD QUARTER 2023 FINANCIAL RESULTS
Rhea-AI Summary
Greenbrook TMS Inc. will release its 2023 third quarter operational and financial results on November 8, 2023. A conference call will be held on November 9, 2023 to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.64%
Tags
earnings
-
News
GREENBROOK APPOINTS INTERIM CHIEF FINANCIAL OFFICER
Rhea-AI Summary
Greenbrook TMS Inc. appoints Peter Willett as Interim Chief Financial Officer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6%
Tags
management
-
News
GREENBROOK TMS RAISES US$1.5 MILLION IN DEBT FINANCING
Rhea-AI Summary
Greenbrook TMS Inc. receives $1.5 million in debt financing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
GREENBROOK TMS RAISES US$1.9 MILLION IN DEBT FINANCING
Rhea-AI Summary
Greenbrook TMS raises US$1.9 million in debt financing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
none
Stock GBNH logo
Greenbrook TMS Inc

Nasdaq:GBNH

GBNH Rankings

N/A Ranked by Market Cap
#5478 Ranked by Stock Gains
N/A Ranked by Dividends

GBNH Stock Data

5.52M
13.12M
47.89%
30.61%
0.27%
Dental Laboratories
Manufacturing
Link
Canada
Toronto

About GBNH

leading provider of tms therapy. fda-cleared & proven treatment for depression. non-invasive, non-sedating, no drug related side effects. we can help!